Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HealthCore-NERI; New England Research Institutes
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Treatments: Tolterodine Tartrate

Criteria

Inclusion:

• Female

• Urge predominant incontinence

• Incontinent > 3 mos

• Available for 8 mos of followup

Exclusion:

• Pregnancy or < 6 mos post-partum

• Hypersensitivity to drug (tolterodine)

• Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury)

• History of extensive behavior treatment